The MTCL1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with targeted disruption of the MTCL1 gene, providing a heterogeneous loss-of-function model in the Raji B lymphocyte background. This polyclonal format avoids clonal artifacts and reflects natural genetic variation, making it suitable for bulk functional assays and pathway analysis.
The Raji host cell line is a suspension-adapted human B lymphoblastoid line derived from a Burkitt lymphoma patient, latently infected with Epstein-Barr virus (EBV) and expressing B-cell markers CD19 and CD20. As a neoplastic model, Raji cells are widely employed for investigating B-cell malignancies, EBV-driven lymphomagenesis, and chromosomal instability mechanisms.
MTCL1 functions as a microtubule crosslinking factor that stabilizes microtubules and ensures proper mitotic spindle orientation. Additionally, it scaffolds LATS1, facilitating phosphorylation by Aurora A, Aurora B, and CDK1, which in turn promotes LATS1-mediated phosphorylation and cytoplasmic retention of YAP/TAZ transcription coactivators. By linking microtubule dynamics to Hippo signaling, MTCL1 suppresses YAP/TAZ-dependent pro-proliferative gene expression, including targets like CTGF and CYR61. Interacting partners include tubulin, LATS1, and microtubule-associated proteins.
In Raji lymphoma cells, MTCL1 loss likely disrupts microtubule integrity and spindle function, increasing mitotic errors and chromosomal instability??a hallmark of Burkitt lymphoma. Simultaneously, reduced LATS1 activation may derepress YAP/TAZ, enhancing transcription that drives proliferation and survival. This dual role positions MTCL1 as a critical node between cytoskeletal regulation and oncogenic signaling, making the knockout model an essential tool for dissecting molecular contributors to B-cell lymphomagenesis and tumor maintenance.
Experimental applications include Western blotting to verify MTCL1 depletion and monitor LATS1/YAP phosphorylation, immunofluorescence for microtubule visualization, flow cytometry for cell cycle and apoptosis analysis, and RT-qPCR for YAP target genes. Drug sensitivity profiling with Aurora kinase inhibitors or taxanes enables identification of synthetic lethal interactions. Co-immunoprecipitation assays facilitate study of MTCL1?CLATS1 complexes. These approaches support systematic exploration of MTCL1’s roles in B-cell lymphoma, Hippo pathway crosstalk, and microtubule-targeted therapy development. Please contact Ascent Research for further technical details.
